data from its phase three clinical trial with MDMA-assisted therapy for post-traumatic stress disorder, showing that 67% of participants who received three treatments no longer qualified for a PTSD diagnosis and 88% experienced a clinically meaningful reduction in symptoms. Other companies like MindMed, which is studying LSD for anxiety and a modified version of ibogaine to treat opioid-use disorder, have also listed on Nasdaq.
Cybin’s phase two study will be conducted in two parts at Jamaica’s University of West Indies Hospital. The first part of the clinical trial will consist of a Phase IIa study of 40 patients to identify the equivalent dose of Cybin’s sublingual psilocybin formulation compared with a 25 mg pill of psilocybin. Cybin’s sublingual film is designed for rapid absorption, a faster onset, and a shorter duration.
Cybin is starting with psilocybin, but the company is developing novel molecules based on other psychedelic compounds. The company has filed 12 provisional patent applications for novel psychedelic compounds.
Everyone sleeping on AikidoPharma $aiki
Compass Pathways ( CMPS) are a company in this field working on psilocybin and they are on the nasdaq.
Cause This way I will know I am 9n a Trip. 😉
Sign me up.
Very Good............
Hmm akshaat
Where do I sign?
RatkoMartinovic
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Forbes - 🏆 394. / 53 Read more »